- Home
- ALOY vs FLGT Comparison
ALOY vs FLGT Comparison
Compare ALOY & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALOY | FLGT |
|---|---|---|
| Founded | 2024 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 579.9M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ALOY | FLGT |
|---|---|---|
| Price | $13.07 | $18.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $35.00 | $28.33 |
| AVG Volume (30 Days) | ★ 3.0M | 292.4K |
| Earning Date | 06-17-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $692,803.00 | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | N/A | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.83 | $13.46 |
| 52 Week High | $26.90 | $31.04 |
Technical Indicators
Market Signals| Indicator | ALOY | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 61.13 | 45.58 |
| Support Level | $7.62 | $17.64 |
| Resistance Level | $13.75 | $20.10 |
| Average True Range (ATR) | 1.17 | 0.74 |
| MACD | 0.64 | -0.04 |
| Stochastic Oscillator | 94.59 | 60.90 |
Price Performance
Historical ComparisonAbout ALOY REalloys Inc. Common Stock
REalloys Inc is an integrated company focused on the development and production of rare earth elements, with a primary assets.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.